BioSpace News Archive

The global pediatric medical devices market was valued at US$ 25 billion in 2020 and is projected to reach over US$ 41.5 billion by 2027, expanding at a CAGR of 8.5% from 2021 to 2027.

According to Vision Research Reports, the global sepsis treatment market size is predicted to hit US$ 1.5 billion by 2030.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced detailed, longer-term data from the Phase 3 DERBY and OAKS studies of intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

The global diabetic foot ulcers treatment market is projected to reach a market value of US$ 9.6 Bn by the end of 2027.

Gynecological diseases represent a collective term given to different medical conditions specific to the female reproductive system.

According to latest market report on the non-invasive prenatal testing market for the historical period of 2017–2021 and forecast period of 2022–2030, increase in maternal age and increasing demand for early and non-invasive fetal testing procedures are anticipated to drive the global non-invasive prenatal testing market.

The adoption of electrically powered/myoelectric technology is predicted to grow at an aggressive rate during the forecast period.

Passage Bio, Inc. announced that additional clinical and biomarker data from Cohort 1 in the Imagine-1 study for GM1 gangliosidosis will be presented at the upcoming American Society of Gene and Cell Therapy 25th Annual Meeting, which is being held in Washington D.C. and virtually from May 16 to 19, 2022.

X4 Pharmaceuticals, Inc. announced that, on April 29, 2022, the Compensation Committee of X4’s Board of Directors issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), today announced two presentations highlighting the results from a study evaluating diazoxide choline extended-release (DCCR) tablets under development for the treatment of Prader-Willi Syndrome (PWS) in patients who completed its DESTINY PWS study and then continued into the open-label extension clinical study (C601/C602).